Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 29246803

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2018 Jan
First author
Jones JA

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Jan;19(1):7-8. doi: 10.1016/S1470-2045(17)30910-5.
    note
    Source null
    related pmid
    29246804
    relationship
    Comment in

Authors and identifiers

  1. name
    Jones JA
    type
    Author
  2. name
    Mato AR
    type
    Author
  3. name
    Wierda WG
    type
    Author
  4. name
    Davids MS
    type
    Author
  5. name
    Choi M
    type
    Author
  6. name
    Cheson BD
    type
    Author
  7. name
    Furman RR
    type
    Author
  8. name
    Lamanna N
    type
    Author
  9. name
    Barr PM
    type
    Author
  10. name
    Zhou L
    type
    Author
  11. name
    Chyla B
    type
    Author
  12. name
    Salem AH
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Jones JA
    type
    Author
  2. name
    Mato AR
    type
    Author
  3. name
    Wierda WG
    type
    Author
  4. name
    Davids MS
    type
    Author
  5. name
    Choi M
    type
    Author
  6. name
    Cheson BD
    type
    Author
  7. name
    Furman RR
    type
    Author
  8. name
    Lamanna N
    type
    Author
  9. name
    Barr PM
    type
    Author
  10. name
    Zhou L
    type
    Author
  11. name
    Chyla B
    type
    Author
  12. name
    Salem AH
    type
    Author
bibliography ids
  1. nci-bib-82bc590f23ac59715c56c488
book metadata
content sha256
4b7e8c3d3569a5c90b893f26c16d2a9c4ca5577de443b9524f4bd1a1c6d8d449
document type
citation
dois
  1. 10.1016/S1470-2045(17)30909-9
electronic publication date
display
2017 Dec 12
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:29246803
immutable id
pubmed:29246803@4b7e8c3d3569a5c90b893f26c16d2a9c4ca5577de443b9524f4bd1a1c6d8d449
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
1
name
The Lancet. Oncology
nlm unique id
100957246
pages
65-75
volume
19
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Jan;19(1):7-8. doi: 10.1016/S1470-2045(17)30910-5.
    note
    Source null
    related pmid
    29246804
    relationship
    Comment in
outcomes validated
false
pmid
29246803
provenance
batch id
ec9444d0f4cade22eb9f
provider
NCBI PubMed ESummary
record sha256
44297921c692dfce22193347d3a04cf26d14ae6dc965d71d7ce77c5ce59ac482
response sha256
6eef0d8cc09b77e73af656f6390cc734befb84fbc4c229b886e81e5d95bece31
retrieved at
2026-09-09T23:47:30.975610+00:00
publication date
display
2018 Jan
precision
month
year
2018
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/29246803/
title
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.

Preserved source evidence · Not medical advice